E.E. Geduld’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

E.E. Geduld’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-7,530	Closed	-$241K	–	277
2015 Q2	$241K	Sell	7,530 -2,500	-25%	-$63.4K	0.15%	155
2015 Q1	$240K	Buy	+10,030	New	+$225K	0.16%	144
2014 Q2	–	Sell	-20,030	Closed	-$364K	–	344
2014 Q1	$364K	Buy	+20,030	New	+$362K	0.2%	128

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

E.E. Geduld's ITCI Position: Q3 2015 in Review

E.E. Geduld sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2015, closing a stake of 7,530 shares — an estimated $241K sold.

E.E. Geduld first reported a position in ITCI in Q1 2014 and held it in 3 quarters. The position peaked at $364K in Q1 2014. 128 funds tracked by Wall St. Rank hold ITCI as of Q3 2015.

E.E. Geduld reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2015 after selling out during the quarter.
E.E. Geduld sold 7,530 Intra-Cellular Therapies Inc. shares in Q3 2015, an estimated $241K.
E.E. Geduld first reported a position in Intra-Cellular Therapies Inc. in Q1 2014 and held it in 3 quarters.
E.E. Geduld's Intra-Cellular Therapies Inc. position peaked at $364K in Q1 2014.
128 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2015.

Based on E.E. Geduld's 13F filing for Q3 2015, filed 6 Nov 2015.